

Peng Song

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5418690/publications.pdf>

Version: 2024-02-01

17
papers

248
citations

932766

10
h-index

996533

15
g-index

23
all docs

23
docs citations

23
times ranked

419
citing authors

#	ARTICLE	IF	CITATIONS
1	Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese <sc>NSCLC</sc> patients. Thoracic Cancer, 2020, 11, 1621-1632.	0.8	44
2	Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. Thoracic Cancer, 2020, 11, 2406-2430.	0.8	40
3	Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors. Scientific Reports, 2019, 9, 4278.	1.6	26
4	Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients. Thoracic Cancer, 2020, 11, 1647-1654.	0.8	18
5	Correlation Between PD-L1 Expression and Clinicopathologic Features in 404 Patients with Lung Adenocarcinoma. Interdisciplinary Sciences, Computational Life Sciences, 2019, 11, 258-265.	2.2	15
6	Curative effect assessment of immunotherapy for non-small cell lung cancer: The "ceblind area" of Immune Response Evaluation Criteria in Solid Tumors (iRECIST). Thoracic Cancer, 2019, 10, 587-592.	0.8	14
7	Eltrombopag treatment for severe refractory thrombocytopenia caused by pembrolizumab. European Journal of Cancer, 2019, 121, 4-6.	1.3	13
8	Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients. Thoracic Cancer, 2019, 10, 1303-1309.	0.8	12
9	<p>Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer</p>. OncoTargets and Therapy, 2019, Volume 12, 8151-8159.	1.0	11
10	Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study. Cancer Medicine, 2021, 10, 188-198.	1.3	11
11	Management of immune checkpoint inhibitor-related adverse events: A review of case reports. Thoracic Cancer, 2020, 11, 498-504.	0.8	10
12	<p>NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score</p>. Cancer Management and Research, 2020, Volume 12, 5975-5985.	0.9	7
13	Refractory chylous pleural effusion with systemic lupus erythematosus. Zeitschrift Fur Rheumatologie, 2019, 78, 797-802.	0.5	5
14	Single-center study to determine the safety and efficacy of CT-707 in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer. Thoracic Cancer, 2020, 11, 1216-1223.	0.8	5
15	<p>Refinement of diagnosis and supporting evidence for the use of immunotherapy through sequential biopsies in a case of EML4-ALK positive lung cancer</p>. OncoTargets and Therapy, 2019, Volume 12, 2943-2948.	1.0	3
16	Alectinib treatment response in lung adenocarcinoma patient with novel <i>EML4-ALK</i> variant. Thoracic Cancer, 2018, 9, 1327-1332.	0.8	2
17	Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor-associated adverse events. Thoracic Cancer, 2020, 11, 2077-2086.	0.8	1